Retatrutide vs Bariatric Surgery: The Short Answer

On average weight loss, retatrutide's main Phase 3 results are in a similar range to what the two most common operations reach in their first year, though in different patients and over different timeframes, and surgery's results have been followed far longer.

• Retatrutide 12 mg (TRIUMPH-1): 25.0% of total body weight at 80 weeks counting everyone randomized, or 28.3% if taken as intended.
• Gastric bypass: about 31% of total body weight at 1 year and 26% at 5 years, in a US study of more than 46,000 surgery patients.
• Sleeve gastrectomy: about 25% at 1 year and 19% at 5 years in the same study.

These figures come from different kinds of evidence: a placebo-controlled trial for retatrutide, and records of routine surgical care for the operations. No trial has compared retatrutide with surgery directly, and retatrutide's longest follow-up so far is two years (104 weeks).

The two are studied in different people and followed for very different lengths of time, so a simple "which is better" answer is not supported by the evidence.

How Much Weight Loss Retatrutide Produced

In TRIUMPH-1, published in the New England Journal of Medicine in September 2026, 2,339 adults with obesity and without diabetes received retatrutide 4 mg, 9 mg or 12 mg, or placebo, for 80 weeks.

The two columns reflect two ways of counting: everyone who was randomized, including people who stopped treatment, and an estimate of what would have happened if everyone had stayed on treatment as intended. Counting everyone randomized, 36.9% of people on 12 mg lost at least 30% of their body weight, compared with 0.6% on placebo.

In a 24-week extension of about 500 participants (532 with a starting BMI of 35 or more, according to the company), given the highest dose they tolerated (9 mg or 12 mg), those originally assigned to 12 mg had lost 29.9% of their weight at week 104 (30.3% if taken as intended). In TRIUMPH-4, in people with obesity or overweight and knee osteoarthritis, the company reported 28.7% at 68 weeks with 12 mg, if taken as intended. How the loss built up over time is covered in the retatrutide weight loss timeline.

How Much Weight Loss Surgery Produces

The PCORnet Bariatric Study, published in the Annals of Internal Medicine in 2018, followed more than 46,000 adults at 41 US health systems. Measured as a share of total body weight, as in retatrutide's trials:

Surgery results are also often reported as a share of excess weight, meaning the weight above a healthy range, rather than of total body weight. The American Society for Metabolic and Bariatric Surgery (ASMBS) says patients "may lose as much as 77% of their excess weight within the first year depending on the procedure," and that sustained weight loss after 5, 10 and 20 years has been shown across multiple studies.

Retatrutide's trials report the percent change in total body weight. A 28% loss of total weight and a 77% loss of excess weight are different measures and cannot be compared directly, which is why the table above uses total body weight for both. Even then, a trial with strict entry criteria and a registry of everyday surgical patients are not equivalent, so "retatrutide matches sleeve gastrectomy" goes further than the evidence.

Comparing the Two Side by Side

With those limits in mind, here is how the evidence for each currently stands.

Safety: Different Kinds of Risk

ASMBS puts the risk of major complications at about 4% and the risk of death at about 0.1%, varying by procedure.

The risks seen with retatrutide in TRIUMPH-1 were mostly gastrointestinal. With 12 mg, 42.4% of people reported nausea and 25.3% vomiting, compared with 14.8% and 4.8% on placebo, mostly mild or moderate and mostly while the dose was being increased; 11.2% stopped treatment because of side effects, compared with 4.6% on placebo. Serious adverse events occurred in 10.5% of the 12 mg group and 5.5% on placebo. Four people on retatrutide and two on placebo died during the trial.

These figures describe different things: one is the risk of a single procedure, the other the side effects reported during 80 weeks of weekly treatment. Retatrutide's long-term safety beyond two years is not yet known.

What Happens After Stopping

Most weight-loss operations permanently change the digestive tract. For retatrutide, what happens to weight after stopping it has not been reported: TRIUMPH-1 did not test stopping the drug, and TRIUMPH-6, a separate trial, is studying maintenance of weight reduction. The evidence on stopping is covered in weight regain after stopping retatrutide.

Retatrutide After Bariatric Surgery

Some people ask whether retatrutide could be used after a sleeve gastrectomy or other weight-loss surgery. There is no answer from the evidence yet. The main text of the TRIUMPH-1 paper does not describe whether people with previous bariatric surgery could take part, and we found no published retatrutide trial in people who have had weight-loss surgery.

What Is Still Unknown

• How retatrutide and surgery compare in the same kind of patients, measured the same way.
• How long retatrutide's weight loss lasts, on or off treatment, beyond two years.
• Whether retatrutide reduces heart attacks, strokes or deaths; this is being studied in TRIUMPH-Outcomes.
• Whether retatrutide is safe and effective after bariatric surgery.

Retatrutide is not approved for any use. Lilly plans to submit it to the US Food and Drug Administration in the first quarter of 2027.

Sources

• Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
• Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025. (TRIUMPH-4)
• Arterburn D, Wellman R, Emiliano A, et al. Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study. Ann Intern Med. 2018;169(11):741–750.
• Kaiser Permanente Washington Health Research Institute. Gastric bypass surgery is best for weight loss for severe obesity. October 29, 2018.
• American Society for Metabolic and Bariatric Surgery. Metabolic and Bariatric Surgery fact sheet. 2025.
• Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.

Medical Disclaimer: This article compares published evidence for general information only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and products sold online under its name are not sold or supplied by Lilly. Nothing here is a recommendation for or against surgery or any medication.